<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99054">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01792258</url>
  </required_header>
  <id_info>
    <org_study_id>53/12</org_study_id>
    <nct_id>NCT01792258</nct_id>
  </id_info>
  <brief_title>Procedures and Follow-up of Percutaneous Tracheostomy in Intensive Care Unit</brief_title>
  <official_title>Procedures, Complications and Follow-up of Percutaneous Tracheostomies in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Genova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Genova</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tracheostomy is worldwide performed in Intensive Care Unit (ICU). According to the current
      literature, indication for percutaneous tracheostomy (PDT) in ICU are: difficult prolonged
      weaning, prolonged mechanical ventilation, loss of airway reflex, copious secretions, upper
      airway obstruction. Many studies have focused on the comparison between different PDT
      techniques and complication. The aim of our study is to evaluate the procedural features,
      complications, ICU mortality, quality of life, post-discharge mortality of patients
      undergoing different PDT techniques performed in ICU.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Safety of percutaneous tracheostomy</measure>
    <time_frame>at the beginning and at the end of the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early complications</measure>
    <time_frame>in the first 24 hours from the end of the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Early complications are:multiple intubation attempts (more than 1), accidental extubation, paratracheal insertion, injuries to blood vessels in the neck, oesophageal injury, accidental decannulation, malposition of the tracheostomy tube, tracheal cuff puncture, multiple punctures (more than 1), surgical conversion and percutaneous tracheostomy failure, minor bleeding (compressible), major bleeding (incompressible), pneumothorax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late complications</measure>
    <time_frame>from the 2nd day ofter the procedure until the ICU discharge (expected average of 2 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Late complications are: minor bleeding (compressible), major bleeding (incompressible) tracheostomy puncture site infection, subglottic stenosis, fracture of a tracheal cartilage, granuloma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at 3, 6 and 12 months after tracheostomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The investigator will use the EURO-QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of organ function</measure>
    <time_frame>At 3, 6 , and 12 months after tracheostomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The investigator will perform a flexible fiberoptic laryngoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of voice</measure>
    <time_frame>At 3,6, 12 months after tracheostomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the investigator will use a KAY elemetrics analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 3, 6 and 12 months from tracheostomy</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <condition>Neurological Disease</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>critical ill patients</arm_group_label>
    <description>The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous tracheostomy</intervention_name>
    <description>Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.</description>
    <arm_group_label>critical ill patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Criticall ill patients requiring percutaneous tracheostomy in intensive care unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18

          -  indication for tracheostomy

        Exclusion Criteria:

          -  infectious disease of neck
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Pelosi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Genoa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Genoa</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 12, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Genova</investigator_affiliation>
    <investigator_full_name>Paolo Pelosi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Percutaneous tracheostomy</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Ineffective Airway Clearance</keyword>
  <keyword>Weaning failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
